Reported a net loss of $6.9 million for the three months ended March 31, 2026, compared to a net loss of $17.4 million in the same period of 2025. Operating expenses totaled $8.1 million, driven by increased research and development and general and administrative costs. Cash and cash equivalents were $3.0 million as of March 31, 2026, with an additional $12.1 million in short-term investments. Successfully implemented a 1-for-25 reverse stock split effective April 2, 2026, to regain compliance with Nasdaq minimum bid price requirements. Completed an underwritten public offering in January 2026, raising approximately $13.9 million in net proceeds.